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Endocannabinoids regulate different aspects of neurodevelopment. In utero exposure 
to the exogenous psychoactive cannabinoid Δ9-tetrahydrocannabinol (Δ9-THC), has 
been linked with abnormal cortical development in animal models. However, much 
less is known about the actions of endocannabinoids in human neurons. Here we 
investigated the effect of the endocannabinoid 2-arachidonoyl glycerol (2AG) and Δ9-
THC on the development of neuronal morphology and activation of signaling kinases, 
in cortical neurons derived from human induced pluripotent stem cells (hiPSCs). Our 
data indicate that the cannabinoid type 1 receptor (CB1R), but not the cannabinoid 2 
receptor (CB2R), GPR55 or TRPV1 receptors, is expressed in young, immature 
hiPSC-derived cortical neurons. Consistent with previous reports, 2AG and Δ9-THC 
negatively regulated neurite outgrowth. Interestingly, acute exposure to both 2AG and 
Δ9-THC inhibited phosphorylation of serine/threonine kinase extracellular signal-
regulated protein kinases (ERK1/2), whereas Δ9-THC also reduced phosphorylation 
of Akt (aka PKB). Moreover, the CB1R inverse agonist SR 141716A attenuated the 
decrease in neurite outgrowth and ERK1/2 phosphorylation induced by 2AG and Δ9-
THC. Taken together, our data suggest that hiPSC-derived cortical neurons express 
CB1Rs and are responsive to exogenous cannabinoids. Thus, hiPSC-neurons may 
represent a good cellular model for investigating the role of the endocannabinoid 







The endocannabinoid system is a neuromodulatory system with important roles 
in central nervous system (CNS) development, neuronal function and synaptic 
plasticity (Gaffuri et al., 2012; Lu and Mackie, 2016). The endocannabinoid system is 
composed of endogenous cannabinoids, enzymes that synthesize and degrade 
endogenous cannabinoids and cannabinoid receptors. The cannabinoid 1 receptor 
(CB1R) is a highly abundant receptor in the CNS, with strong expression in a number 
of brain regions including the cortex (Lu and Mackie, 2016; Matsuda et al., 1990). 
Cannabinoid 2 receptor (CB2R) show much lower expression in the CNS, although 
recent work has shown high inducible expression of CB2Rs under pathological 
conditions (Miller and Devi, 2011). Several other receptors, such as peroxisome 
proliferator activated receptors and transient receptor potential channels, are also 
engaged by cannabinoids (Pertwee et al., 2010). 
CB1Rs are members of the superfamily of G protein-coupled receptors that 
inhibit adenylyl cyclase and activate mitogen-activated protein kinase by signaling 
through Gi/o proteins. Stimulation of CB1R by cannabinoids has been shown to lead 
to the phosphorylation of serine/threonine kinase Akt and extracellular signal-
regulated kinase ERK1/2 (Derkinderen et al., 2003). These kinases may then activate 
or inhibit their substrates to influence cellular functions such as promoting survival, 
metabolism and differentiation. Both Akt and ERK1/2 activation have been shown to 
mediate neurite outgrowth (Wang et al., 2011; Zheng et al., 2008), a key process in 
neuronal development and plasticity. The primary psychoactive component of 
cannabis (Cannabis sativa), Δ9-tetrahydrocannabinol (Δ9-THC) is also thought to act 
via the CB1R, resulting a wide range of effects including a depression of the 
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glutamatergic system (Lu and Mackie, 2016). Perturbations in the endocannabinoid 
system have been implicated in psychiatric disorders such as schizophrenia (Murray 
et al., 2017). A number of studies have reported a significant association between 
cannabis use and schizophrenia (Appiah-Kusi et al., 2016; Di Forti et al., 2019; Murray 
et al., 2017; Pasman et al., 2018). However, a causal link between cannabis use and 
schizophrenia remains controversial (Murray et al., 2017). It has been argued that 
there is no evidence that cannabis use triggers psychosis and that the reported effects 
are due to the individuals already being genetically at risk of schizophrenia (DeLisi, 
2008). Conversely, a number of studies have demonstrated that exposure to Δ9-THC 
induce psychotic-like symptoms in healthy individuals (Bhattacharyya et al., 2010). 
Furthermore, in individuals diagnosed with schizophrenia, an acute challenge with Δ9-
THC has been reported to worsen positive symptoms (D'Souza et al., 2005). The 
consequence of perinatal cannabis exposure has also become of interest, with reports 
of alter development in off spring in animal models (Tortoriello et al., 2014) and long 
lasting functional consequences in human and animal models (Scheyer et al., 2019). 
These controversies highlight the need to better understand the impact that 
cannabinoids have during human development to better understand the potential 
detriment effects of perinatal exposure to cannabis. 
Much of our knowledge of the endocannabinoid system comes from work using 
in vitro and in vivo animal models. It remains unknown how well these data translate 
to the human neurons. Investigations into the role of endocannabinoids during cortical 
development have shown that cannabinoids are important axon guidance cues and 
that endocannabinoid signaling regulates neuronal projection growth and target 
innervation (Argaw et al., 2011; Berghuis et al., 2007). Furthermore, cannabinoids 
regulate neuronal morphology through the regulation of small GTPase signaling 
5 
 
pathways and the actin cytoskeleton, resulting in a negative impact on cortical 
development (Njoo et al., 2015; Roland et al., 2014; Tortoriello et al., 2014). Advances 
in stem cell technology have enabled the reprogramming of human somatic cells into 
induced pluripotent stem cells (hiPSCs) (Takahashi et al., 2007; Takahashi and 
Yamanaka, 2006), which can subsequently be differentiated in to specific neuronal 
subtypes (Parr et al., 2017). Using this system Guennewig and colleagues 
demonstrated that exposure of hiPSC-neurons to Δ9-THC resulted in significant 
altered expression of genes involved in development, synaptic function, as well as 
those associated with psychiatric disorders (Guennewig et al., 2018). This supports 
the use of hiPSCs as a cellular model to investigate the cellular actions of 
cannabinoids to understand their relevance for health and disease.  
In this study, we first examined the expression of cannabinoid receptors during 
the differentiation of hiPSCs into cortical neurons. Subsequently, we investigated the 
impact of acute exposure to the endogenous cannabinoid 2-arachidonoyl glycerol 
(2AG), a full agonist for the CB1R, and Δ9-THC, a partial agonist for CB1R, on the 
morphology of young hiPSC-derived cortical neurons. Furthermore, we assessed the 
ability of 2AG and Δ9-THC to regulate the activity of ERK1/2 and Akt signaling 
cascades. Finally, we report that the CB1R inverse agonist SR 141716A 
(Rimonabant), attenuated the negative regulation of neurite outgrowth and ERK1/2 
phosphorylation induced by 2AG and Δ9-THC. Taken together, our data indicates that 
CB1Rs are expressed in immature hiPSC-neurons and that 2AG and Δ9-THC 
treatment negatively affect neuronal morphology and impact the Akt and ERK1/2 
signaling pathways, potentially via CB1R.  
 





 Δ9-THC (ethanol solution, ab120447) were from Abcam. 2-Arachidonylglycerol 
(1298), U0126 (1144) and SR 141716A (0923) were from Tocris. Δ9-THC was 
prepared by serially diluting the solution in culture media to a 10x stock solution. The 
CB1R inverse antagonist SR 141716A was dissolved in DMSO and used at a final 
concentration of 20 nm; an equivalent volume of DMSO or ethanol was used as a 
vehicle control. A list of antibodies used in this study can be found in Table 1. 
 
Human induced pluripotent stem cells (hiPSCs) 
 HiPSC lines (CTM_01_04, CTM_02_05 and CTM_03_22) were generated from 
primary keratinocytes as described previously (Cocks et al., 2014) (Supplementary 
Figure 1A & B). Participants were recruited and methods carried out in accordance 
to the ‘Patient iPSCs for Neurodevelopmental Disorders (PiNDs) study’ (REC No 
13/LO/1218). Informed consent was obtained from all subjects for participation in the 
PiNDs study. Ethical approval for the PiNDs study was provided by the NHS Research 
Ethics Committee at the South London and Maudsley (SLaM) NHS R&D Office.  
 
Neuronal differentiation 
Neuronal differentiation of hiPSCs was achieved by replacing E8 medium on 
confluent hiPSCs with neuralization medium: 1:1 mixture of N2- and B27 (Life 
Technologies) supplemented with 10 μM SB431542 (Sigma-Aldrich) and 1 μM 
Dorsomorpin (Calbiochem) for dual SMAD inhibition (2i). Cells were maintained at 
37°C in normoxic conditions in 2i medium for 7 days with media was replacement 
every 24 hours. At day 7 the 2i induced neuroepithelial cells were then passaged using 
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Accutase (Life Technologies) and re-plated at a 1:1 ratio in N2:B27 media without the 
small molecule inhibitors and supplemented with 10 μM Rock Inhibitor Y-27632 
(Sigma Aldrich) until day 12. Cells were then passaged 2 more times following the 
same procedure described above at days 16 and 20. During neuronal induction, the 
formation of neural rosettes was evident from approximately day 10 until the 
differentiation of neural progenitors (NPC) around day 20. NPCs were maintained as 
mitotic progenitors in neuralization medium supplemented with 10 ng/ml bFGF, 5 
µg/ml insulin, 1 mM l-glutamine, 100 µm non-essential amino acids, and 100 µM 2-
mercaptoethanol. NPC were terminally plated on 5 µg/ml poly-D-lysine and 2 µg/cm2 
laminin (Thermo Fisher) in  B27 medium supplemented with 200 µM L-ascorbic acid 
and 10 µM DAPT (Calbiochem) for 7 days (day 27) to block NOTCH signaling. 
Neurons were grown in B27 medium with 200 µM L-ascorbic acid until day 30 when 
they were used for experimentation.  
 
Treatments 
 Acute pharmacological treatment (15 or 30 minutes) of cells was performed in 
ACSF solution (125 mM NaCl, 2.5 mM KCl, 26.2 mM NaHCO3, 20 mM glucose, 5 mM 
Hepes, 2.5 mM CaCl2 and 1.25 mM MgCl2). Prolonged pharmacological treatment (24 
hour) was performed in Neurobasal medium supplemented with B27 and 200 µM L-
ascorbic acid.  
 
qRT-PCR 
 Total RNA harvested and lysed with Trizol reagent (Life technologies) and 
isolated by centrifugation with 100% Chloroform, following by 100% isopropanol and 
lastly by 75% ethanol. The RNA was purified by precipitation with 100% ethanol and 
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Sodium acetate (Life technologies) and quantify with the NanoDrop 1000 
Spectrophotometer (Thermo scientific). Residual genomic DNA was removed by 
addition of TURBO DNA-free (Life technologies) and incubation at 37°C for 30 
minutes. Complementary DNA (cDNA) was synthesized from 1 µg of total RNA from 
each extraction using random hexamer primers and SuperScript III (Life Technologies) 
following the manufacturer's recommendations. qPCR was performed with HOT 
FIREPol EvaGreen qPCR Mix Plus ROX (Solis Biodyne) carried out according to the 
manufacturer’s instructions in a total volume of 20 µl, containing 1:5 diluted cDNA, 
qPCR mix and primers at to a final concentration of 0.3 μM. PCR reaction conditions: 
95oC for 15 minutes for the initial denaturation followed by 95oC for 30 seconds, 60oC 
for 30 seconds and 72oC for 30 seconds during 33 cycles. The melting curve analyses 
was preformed from 60oC to 95oC with readings every 1oC. The 2^ Δ Δ CT comparative 
method for relative quantification was used to quantify the genes expression. The data 
CT values were normalized to GAPDH, RPL27 and SDHA housekeeping genes.  
 
Immunocytochemistry 
Treated neurons were fixed with 4% formaldehyde plus 4% sucrose in PBS. 
Fixed neurons were permeabilized in 0.1% Triton-X-100 in PBS for 15 minutes and 
blocked in 4% normal goat serum in PBS for 1 hour at room temperature. Primary 
antibodies were added to the block solution in an antibody dependent concentration 
and incubated overnight at 4°C. Immunoreactivity was achieved by incubating the cells 
with 1:500 concentration of Alexa Fluor 594 conjugated anti-mouse IgG, Alexa Fluor 
594 conjugated anti-goat IgG and Alexa Fluor 488 conjugated anti-rabbit IgG in block 




Imaging of immunofluorescence by high content image screening 
 NPCs were plated at a density of 1x104 cells/well on poly-D-lysine and laminin-
coated optical-bottom 96 well plates with polymer base (ThermoScientific). Image 
acquisition was performed with a 20X objective for the genes OCT4, NANOG, SOX11, 
ZNF521, PAX6, NESTIN, FOXG1, TBR1, TBR2 and BRN1 by using CellInsight CX5 
High Content Screen Platform (Thermo Fisher). The bioapplication Cell Health 
Profiling from the iDev software package (Thermo Fisher) using the nuclear staining 
to assess viable cells. Intensity, shape and size features were used to determine 
positively labelled cells.  
For neurite outgrowth assays, treated hiPSC-neurons were imaged using an 
Opera Phenix High Content screening platform (Perkin Elmer): images were acquired 
using a 20 x (NA 0.4) objective. The Harmony High Content Imaging and Analysis 
Software was used to determine the average neurite length and average branch 
number based on the MAP2 staining. For each hiPSC line, 3 biological replicates with 
3 technical replicates per condition were imaged and analyzed: 15 randomly selected 
fields from each technical replicate was examined. Data from each technical replicate 
was averaged and used as a single data point and compared with each biological 
replicate and each hiPSC line. The means of percentages of positive cells and the 
average neurite length and branch number were compared by an ANOVA. Confocal 
images of hiPSC-neurons stained for MAP2 and CB1R were acquired using a Lecia 
SP5 confocal microscope using a 63x oil objective (NA 1.4) as a z-series. Post image 





 hiPSC-neurons cells were lysed in 20 mM Tris, pH 7.2, 150 mM NaCl, 1% 
Triton-X-100, 5 mM EDTA pH 8 containing a cocktail of protease and phosphatase 
inhibitors (1mg/ml leupeptin, 5mg/ml aprotinin, 1M NaF, 1mg/ml pepstatin, 100mM 
AEBSF, and Ser/Thr phosphatase inhibitor cocktail #3). Detergent soluble lysate were 
resolved by SDS-PAGE, then immunoblotted with primary antibodies overnight at 4°C, 
followed by incubation with anti-mouse Alexa Fluor 680 and anti-rabbit Alexa Fluor 
790 IgG (H+L) secondary antibodies for 1 hour at room temperature. Membranes were 
scanned with Odyssey imaging system (LI-COR). Intensities of bands were quantified 
by densitometry using Image J (rsb.info.nih.gov/ij/). Full length blots are shown in 
Supplemental Figures 3, 5, 6 and 7. 
 
Statistical analysis 
 All statistical analysis was performed in GraphPad. Differences in 2^ Δ Δ CT, 
relative expression, cell number and neurite parameters were identified by Student's 
unpaired t-tests, or for comparisons between multiple conditions the main effects and 
simple effects were probed by one-way-ANOVAs or two-way-ANOVAs with Tukey or 
Bonferroni correction for multiple comparisons. Differences were considered 
significant if P was lower than 0.05 (p < 0.05). Error bars represent standard errors of 




Generation of cortical neurons from hiPSCs  
Within the developing CNS, the endocannabinoid system has been implicated 
in important neuronal processes such as synapse formation and neurogenesis (Gaffuri 
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et al., 2012; Lu and Mackie, 2016). CB1Rs are G-protein coupled receptors that are 
widely expressed in the brain (Matsuda et al., 1990), including the cortex (Gaffuri et 
al., 2012; Lu and Mackie, 2016). Consistent with a role for the endocannabinoid 
system during the development of cortical neurons, acute (24 hour) exposure of 
hiPSC-neurons to Δ9-THC results in the differential expression of multiple genes, 
including those involved in development (Guennewig et al., 2018). Therefore, in order 
to further understand the role of cannabinoids during the development of human 
cortical neurons, we induced cortical differentiation from hiPSC. The cell lines were 
derived by reprogramming keratinocytes from 3 neurotypic males (age ranging 
between 35 to 55 years: CTM_01_04, CTM_02_05 and CTM_03_22; Supplementary 
Figure 1A and B) (Cocks et al., 2014; Deans et al., 2017; Kathuria et al., 2018; Shum 
et al., 2015). HiPSC lines were differentiated into neuroepithelial cell using a dual 
SMAD inhibition (2i) differentiation protocol for 8 days (Cocks et al., 2014; Deans et 
al., 2017; Shum et al., 2015) (Figure 1A). The small molecule inhibitors were removed 
during neuronal progenitor’s differentiation before media was replaced with B27 
supplemented with DAPT to induce the generation of terminally differentiated neurons 
(Cocks et al., 2014; Deans et al., 2017; Shum et al., 2015) (Figure 1A). 
Immunocytochemical (ICC) analyses indicated that the derived hiPSC expressed high 
levels of the pluripotency markers OCT4, NANOG and SOX11, whereas early neural 
progenitor cell (NPC) markers PAX6, ZNF521 and NESTIN were up regulated 
following 8 days of 2i induction (Figure 1B and 1C). After 26 days of neuronal 
differentiation young neurons expressed high levels of the transcription factors 
FOXG1, TBR1 and TBR2, which are required for the differentiation of cortical neurons 
(Figure 1B and 1C). Similarly, real time PCR (qPCR) analyses demonstrated that the 
neuroepithelial marker SOX2 was highly expressed 7 days after 2i induction and was 
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gradually down-regulated during the 50 days of neuronal fate acquisition (Figure 1D). 
PAX6, a key regulator of cortical development, was found to be highly expressed from 
day 7 to day 50 during neuronal formation; peak expression was observed at day 22 
(Figure 1E). The expression of CTIP2, a marker of deep layer cortical cell fate, rapidly 
increased from day 24 to day 30, peaking at day 26; subsequently, expression of 
CTIP2 was down-regulated until day 50 (Figure 1F). Conversely, expression of BRN2, 
a marker associated with upper cortical layer cell fate, showed expression peaks at 
days 23, 26 and once more at day 40 (Figure 1G). At day 30, few or no GFAP or 
S100β positive cells were observed (Supplementary Figure 2A). ICC analysis at day 
50 revealed that most MAP-positive cells were also immunoreactive for markers of 
glutamatergic fate. This included the pre-synaptic proteins synapsin 1 and VGlut1 and 
the post-synaptic proteins PSD95 and GluN1-subunit of NMDA receptors 
(Supplementary Figure 2B-D). To confirm that hiPSC-neurons generated from a 
hiPSC line derived from keratinocytes, and following our 2i cortical protocol, develop 
physiological neuronal characteristics as previously described (Kathuria et al., 2018; 
Shi et al., 2012), we conducted whole-cell patch clamp recordings in hiPSC-neurons 
differentiated for 64 days. Current clamp recordings demonstrated that these cells 
were capable of firing an action potential in response to current injection 
(Supplementary Figure 2E). Depolarising step potentials (from a holding potential of 
-60mV) evoked transient inward currents and sustained outward currents, indicative 
of activation of voltage gated sodium channels and potassium channels respectively 
(Supplementary Figure 2F). At this age, we were able to record isolated spontaneous 
excitatory postsynaptic currents (EPSCs), demonstrating the potential presence of 
functional excitatory synaptic connections at this stage (Supplementary Figure 2G). 
These data are consistent with previous studies indicating that hiPSC-neurons 
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generated using the 2i protocol develop physiological characteristics; however, the 
remaining data in this study were produced using hiPSC-neurons at an earlier 
developmental stage.  
 
CB1R expression during the cortical differentiation of iPSCs  
Previous studies have suggested that CB1Rs are highly expressed during 
neuronal development (Lu and Mackie, 2016). Therefore, we examined the expression 
of CB1R mRNA in hiPSC-derived NPCs and terminally differentiated neurons. In all 
three hiPSC lines, CB1R showed similar expression patterns. Specifically, CB1R 
mRNA levels significantly increased as hiPSCs differentiated from NPCs into neurons 
(Figure 2A). We further examined the expression of enzymes involved in 
endocannabinoid synthesis and metabolism. Expression of DAGLA increased as cells 
differentiate into neurons (Supplementary Figure 3A). Interestingly, both FAAH and 
MGLL were expressed at similar levels in both NPC and neurons (Supplementary 
Figure 3A). We also examined the expression of CB2R, GPR55 and TRPV1 receptors 
which are expressed in the brain and are engaged by cannabinoids in differentiated 
neurons (Gaffuri et al., 2012; Lu and Mackie, 2016). The mRNA expression levels of 
these receptors were mirrored across the three hiPSC lines and was significantly lower 
compared with the expression of CB1R (Figure 2B). Next, we examined the 
expression of CB1R protein in immature hiPSC-neurons using an antibody raised 
against the C-terminal of the receptor; this antibody has been validated in knockout 
tissue and human tissue (Bjorklund et al., 2011; Chung et al., 2009) as well by pre-
absorption studies (Supplemental Figure 3B). Western blotting demonstrated that 
the receptor was expressed at the protein level in immature hiPSC-neurons. A 
prominent band ~53 kDa consistent with the predicted molecular weight for the 
14 
 
receptor, was readily observed (Figure 2C; Supplemental Figure 3C). Consistent 
with these data, immunostaining of immature hiPSC-neurons revealed that CB1R 
staining could be observed in all three hiPSC clonal lines. CB1R immunoreactivity 
could be observed as in punctate structures along MAP2-positive neurites (Figure 
2D). Collectivity, these data demonstrate that CB1Rs are expressed in immature 
hiPSC-neurons. 
 
2AG and Δ9-THC decrease neurite outgrowth in hiPSC-neurons. 
There is growing appreciation that the endocannabinoid system is an important 
regulator of brain wiring during development through the modulation of several 
different processes including the specification of neuronal morphology (Njoo et al., 
2015; Roland et al., 2014; Vitalis et al., 2008; Watson et al., 2008; Wu et al., 2010). 
As CB1Rs are localized along the neurite, we reasoned that endocannabinoids may 
be involved in regulating the establishment of neuronal morphology in hiPSC-neurons. 
To test this prediction, we first treated hiPSC-neurons at day 29 with 1 µM 2AG, a full 
agonist for the CB1R, for 24 hours. Neurons were then fixed and stained for MAP2 to 
outline neuronal morphology. Neurite outgrowth was assayed using a high-content 
screening platform (Figure 3A). We first assessed whether treatment with 2AG altered 
the number of MAP2-positive cells; this revealed no differences between conditions in 
neurons derived from all 3 hiPSC lines (Figure 3B; p=0.931). We next examined 
neuronal morphology and demonstrated that the average number of neurites (Figure 
3C; p=0.713) and number of branch points (Figure 3D; p=0.780) were unaffected by 
treatment in neurons derived from all 3 hiPSC lines. However, 2AG treatment for 24 
hours significantly reduced neurite length (Figure 3E; F(1,18)=23.4, p < 0.001, 
Bonferroni Post Hoc, * p < 0.05; two-way ANOVA; n = 3 independent cultures per 
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hiPSC line) in neurons derived from all 3 hiPSC lines. Interestingly, a lower 
concentration (50 nM) of 2AG did not significantly alter neurite length in all 3 hiPSC-
lines (Supplemental Figure 4A; P=0.475). 
Δ9-THC has previously been shown to negatively regulate neurite outgrowth 
and growth cone dynamics, through the regulation of actin polymerization and 
microtubule stability in mouse cortical neurons (Njoo et al., 2015; Tortoriello et al., 
2014; Vitalis et al., 2008). In addition, exposure to Δ9-THC in hiPSC-neurons results 
in the altered expression of multiple genes involved in the development of neuronal 
morphology (Guennewig et al., 2018). Therefore, we next examined whether acute 
exposure to Δ9-THC could also alter neurite outgrowth. D29 hiPSC-neurons were 
treated with 3 µM Δ9-THC for 24 hours before neuronal morphology was examined 
using a high-content screening platform (Figure 4A). Δ9-THC treatment did not 
significantly affect the number of MAP2-postive cells across the three hiPSC-lines 
(Figure 4B; p=0.647). Similar to 2AG, exposure to Δ9-THC did not significantly alter 
neurite number (Figure 4C; p=0.426) or branch points (Figure 4D; p=0.859). 
However, Δ9-THC treatment for 24 hours significantly reduced the neurite length 
(Figure 4E; F(1,18)=26.05, p < 0.001, Bonferroni Post Hoc, * p < 0.05; two-way 
ANOVA; n = 3 independent cultures per hiPSC line) in neurons derived from all 3 
hiPSC lines. A lower concentration of Δ9-THC (50 nM) had no effect on neurite length 
in all 3 hiPSC-lines (Supplemental Figure 4B; P=0.266). Taken together, these data 
indicate that both 2AG and Δ9-THC decreases neurite outgrowth in young hiPSC-
neurons. 
 
2AG and Δ9-THC modulate phosphorylation of serine/threonine kinases Akt and 
mitogen-activated protein kinase ERK1/2.  
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Stimulation of CB1R leads to the phosphorylation and activation of several 
signaling kinases, including Akt, ERK1/2 and GSK3β (Derkinderen et al., 2003; Gaffuri 
et al., 2012; Ozaita et al., 2007). Akt and ERK1/2 pathways have also been implicated 
in promoting neurite outgrowth(Wang et al., 2011),(Zheng et al., 2008). GSK-3β, a 
well-defined substrate of Akt, has also been implicated in the regulation of neurite and 
axonal outgrowth and branching (Namekata et al., 2012). Interestingly, the negative 
effects of CB1R activation on neurite outgrowth have been linked with ERK1/2 
signaling (Guennewig et al., 2018), although activation of CB1R has also been linked 
with Akt and GSK3β signaling in vivo (Ozaita et al., 2007). Therefore, we first 
examined 2AG generated changes in the activation state (phosphorylation) of ERK1/2, 
Akt and GSK3β kinases in day 30 hiPSC-neurons. Remarkably, 2AG treatment 
resulted in a significant decrease in ERK1/2 phosphorylation after 30 minutes (Figure 
5A). Conversely, no changes in the phosphorylation state of Akt or GSK3β were 
detected following 15 and 30 minutes of 2AG exposure (Figure 5B and C). These 
data demonstrated that 2AG, a full agonist for the CB1R, is capable of decreasing 
ERK1/2 activity. 
Owing to our data demonstrating that 2AG negatively regulated ERK1/2 
phosphorylation, we next investigated the effect of Δ9-THC on ERK1/2, Akt and 
GSK3β kinases. D30 hiPSC-neurons were treated with vehicle or 3 µM Δ9-THC for 
either 15 or 30 minutes. Similar to 2AG treatment, Δ9-THC induced a rapid decrease 
in ERK1/2 phosphorylation (Figure 5D). Interestingly, Δ9-THC also caused a rapid 
reduction in levels of phosphorylated Akt, which was evident after 15 minutes (Figure 
5E). No change in phosphorylated GSK3β was observed following Δ9-THC treatment 
(Figure 5F). Collectively, these data indicate that Δ9-THC decreases both ERK1/2 and 




2AG and Δ9-THC modulation of kinase activity and neurite outgrowth is blocked 
by CB1R receptor antagonism. 
 As our data indicated that 2AG negatively regulated ERK1/2 and that Δ9-THC 
decreased the activity of both ERK1/2 and Akt signaling kinases, we were interested 
in understanding whether these effects were being mediated by the CB1R. Recently, 
Obiorah et al. showed that Δ9-THC mediated changes in glutamate receptor gene 
expression in hiPSC-neurons could be blocked using the CB1R selective inverse 
antagonist SR 141716A (Rimonabant) (Obiorah et al., 2017). Pre-treatment with 20 
nM SR 141716A blocked 2AG and Δ9-THC (30 minutes) induced de-phosphorylation 
of ERK1/2; SR 141716A alone had not effect on pERK1/2 levels (Figure 6A; 
F(1.309,2.618)=12.07, p = 0.0489, Tukey Post Hoc, * p < 0.05; one-way ANOVA). As 
previously seen, Δ9-THC, but not 2AG (30 minutes) caused a reduction in pAkt levels. 
This effect was blocked by pre-treatment with 20 nM SR 141716A (Figure 6B; 
F(1.542,3.083)=14.15, p = 0.0291, Tukey Post Hoc, * p < 0.05; one-way ANOVA).  
 As our data indicated that the CB1R mediates the effects of 2AG and Δ9-THC 
on ERK1/2 activity, we next questioned whether this receptor was required for the 
decrease in neurite outgrowth induced by these cannabinoids. To test this, we treated 
day 29 hiPSC-neurons with 2AG or Δ9-THC with or without SR 141716A. Treatment 
with 2AG or Δ9-THC caused a reduction in total neurite length; this was attenuated by 
co-treatment with SR 141716A (Figure 7A and B; F(2,36)=6.524, p=0.0038, 
Bonferroni Post Hoc, * p < 0.05, ** p < 0.01, *** p < 0.001; two-way ANOVA; n = 3 
independent cultures per hiPSC line). Next, we reasoned that if 2AG or Δ9-THC were 
causing a reduction in neurite outgrowth by negatively regulating the ERK1/2 pathway, 
that inhibiting this kinase pathway would mimic the effects of these cannabinoids on 
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neurite outgrowth. Therefore, we treated day 29 hiPSC-neurons with 10 μM U0126, a 
MEK inhibitor. Assessment of neurite outgrowth on day 30 revealed that neurons 
treated with U0126 had reduced total neurite length (Supplementary Figure 8A and 
B; F(1,8)=24.1, p=0.0012, Bonferroni Post Hoc, * p < 0.05; two-way ANOVA; n = 3 
independent cultures per hiPSC line). Taken together, these data indicate that 
antagonism of the CB1R by SR 141716A or is sufficient to attenuate the negative 




Recently it has been demonstrated that cannabinoid treatment affects neuronal 
function and glutamate receptor expression in hiPSC-derived dopaminergic neurons 
and excitatory neurons, respectively (Obiorah et al., 2017; Stanslowsky et al., 2017). 
Moreover, treatment with Δ9-THC induces a wide range of transcriptional changes in 
cortical hiPSC-neurons. This includes changes in the expression of genes involved in 
neurodevelopmental processes, as well as those associated with neurodevelopmental 
and psychiatric disorders (Guennewig et al., 2018). Despite this, it is not clear what 
role the endocannabinoid system plays during neurodevelopment. In this study, we 
demonstrate that the CB1R is the major cannabinoid receptor expressed during early 
differentiation of cortical hiPSC-neurons. Furthermore, we demonstrate that treatment 
with either 2AG or Δ9-THC decreased neurite outgrowth, as well as differential effects 
on the activation status of ERK1/2 and Akt signaling kinases. Furthermore, the effect 
of 2AG and Δ9-THC on kinase activity and neurite outgrowth could be blocked by the 




 Previously, Stanslowsky et al. (2017) observed an upregulation of CB1R 
mRNA following terminal differentiation of hiPSC-derived dopaminergic neurons and 
the predominant expression of CB1R in hiPSC-derived neural precursors(Stanslowsky 
et al., 2017). CB1R has also been reported to be highly expressed in newly 
differentiated glutamatergic neurons and is labelled in a punctate manner in the soma 
and neurites of these cells suggesting a prominent role for this receptor during this 
developmental time point (Vitalis et al., 2008). In agreement with these reports, we 
observed that CB1R mRNA is differentially up-regulated during neuronal 
differentiation in three hiPSC lines with different genetic background. Moreover, at the 
protein level, we observed CB1R to be expressed in immature hiPSC-derived cortical 
neurons, where it localized in the cell soma and along neurites. Furthermore, we found 
that hiPSC-derived glutamatergic-neurons expressed CB1R mRNA at significantly 
higher levels compared to CB2R, GPR55 and TRPV1. These findings provide support 
for the idea that the CB1R may play an important role in early neurodevelopmental 
processes such as progenitor cell differentiation and neurite outgrowth, prior to the 
formation of synapses. 
The impact of perinatal exposure to cannabis has come to attention of recent 
(Scheyer et al., 2019). In animals and humans Δ9-THC rapidly crosses the placenta. 
The concentrations of Δ9-THC in fetal blood closely approximates that in maternal 
blood. Blood and plasma Δ9-THC levels after smoking or vaporizing cannabis have 
been reported to range from 1.6-210 µg/L, or about 5-667 nM (Hartman et al., 2016; 
Marsot et al., 2016). The concentration of Δ9-THC used in this study is similar to 
previous studies of in vitro and in vivo animal models, but higher than that reported in 
blood and plasma after smoking or vaporizing cannabis. It should be noted that these 
studies were performed on male participants, and it is unclear whether sex differences 
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exist in the pharmacokinetics of Δ9-THC and its metabolites. Studies on the effect of 
cannabinoids on neurite outgrowth have been attempted with various CB1R agonists 
and have produced conflicting results (Gaffuri et al., 2012). Whereas Δ9-THC 
treatment in murine dopaminergic neurons had no effect on morphology (Moldzio et 
al., 2012),  Δ9-THC treatment reduced neurite length in primary neurons from E16.5 
mouse cortices (Tortoriello et al., 2014). Similarly, activation of CB1R by HU210 has 
been shown to trigger neurite outgrowth in Neuro2A cells (Zorina et al., 2010), while 
CB1R agonist WIN55,212-2 negatively regulates dendritic and axonal outgrowth in 
cultured rat hippocampal neurons (Vitalis et al., 2008). We investigated the effects of 
the endogenous cannabinoid 2AG and the exogenous cannabinoid Δ9-THC on 
neuronal morphology. In our study, we observed that both 2AG and Δ9-THC 
decreased total neurite outgrowth in hiPSC-derived glutamatergic neurons. Vitalis et 
al. (2008) previously showed that basal activation of CB1R acts as a negative 
regulatory signal for neuritogenesis, and treatment with inverse agonist AM281 
blocked these effects (Vitalis et al., 2008). Argaw et al. (2011) showed that 
pharmacological treatment with ACEA, a selective CB1R agonist, induced a collapse 
of the growth cone, an important structure for axon pathfinding and neurite outgrowth. 
Conversely, treatment with AM251, a CB1R inverse agonist, increased the surface of 
the growth cone. These findings establish a mechanism through which the CB1R 
affects growth cone structure in the development of the visual system. The high 
content imaging platform used in this study precluded an accurate measurement of 
growth cone size; however, further investigation of the growth cone in hiPSC-neurons 
would provide greater insight of the mechanisms through which cannabinoids may 
regulate neuronal morphology in developing human neurons. Changes in neuronal 
morphology are believed to be related to changes in neuronal function, as different 
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neuronal subtypes vary in the number and amount of axonal and dendritic branches 
and outgrowth. Migrating cortical projection neurons initially have a bipolar morphology 
in the ventricular zone, then transition to a multipolar morphology in the subventricular 
zone or intermediate zone, where cells extend and retract processes dynamically, 
eventually extending an axon prior to resuming radial migration and transforming back 
to a bipolar cell morphology and entering the cortical plate (Tabata and Nakajima, 
2003). Using the developing visual system as a model, Argaw et al. (2011) showed 
that intraocular injection of ACEA induced a decrease in retinal ganglion cell axon 
growth in vivo, whereas intraocular injection of AM251 increased retinal ganglion cell 
collateral length and branch number (Argaw et al., 2011). In this study, the reduced 
total neurite length as a result of cannabinoid treatment suggests a possible 
dysregulation of neuronal projection growth, which could influence the differentiation 
and maturation of hiPSCs into functional cortical neurons. Future examination of axon 
growth would be important as 2AG/Δ9-THC could impact axon guidance differently. It 
is of note that whilst we demonstrate that exogenous application of 2AG or Δ9-THC 
alters neurite outgrowth, this does not definitively show that the endocannabinoids in 
involved in this process in hiPSC-neurons. Future studies where CB1R is directly 
antagonized or genetically knocked out would clarify this point. Nevertheless, data 
from previous studies as well as those presented in this study suggest that 
endocannabinoids may regulate neuronal morphology in developing neurons. 
However, the specific downstream mechanisms underlying this process are not well-
described, and further research is required to delineate how different cannabinoids 




CB1R signaling is a complex process and cannabinoids can phosphorylate and 
activate members of all three families of multifunctional mitogen-activated protein 
kinases, as well as the PI3K/Akt pathway (Howlett, 2005; Sanchez et al., 2003). We 
examined the signal transduction pathways regulated by the activation of CB1Rs, 
focusing on the effect of 2AG and Δ9-THC on the Akt and ERK1/2 pathways. Studies 
on the effect of cannabinoids on these pathways have been attempted with various 
CB1R agonists and have produced conflicting results. Several studies of non-neuronal 
cells and hippocampal slices and hippocampal neurons in living mice previously 
demonstrated that stimulation of CB1Rs by endocannabinoids anandamide, 2AG and 
exogenous Δ9-THC activates ERK1/2 (Bouaboula et al., 1995; Derkinderen et al., 
2003), whereas stimulation of CB1R by selective CB1R agonist ACEA in primary 
cortical neurons did not alter the phosphorylation of ERK1/2 or Akt (Argaw et al., 2011). 
In contrast, an increase in the phosphorylation of Akt and of GSK3β by acute Δ9-THC, 
anandamide and HU-210 administration has been demonstrated in vivo (Kokona and 
Thermos, 2015; Ozaita et al., 2007). In this study, 2AG did not affect the 
phosphorylation and activation of Akt, whereas Δ9-THC reduced the levels of 
phosphorylated Akt. Furthermore, both cannabinoids reduced the levels of 
phosphorylated ERK1/2. These effects were attenuated by co-treatment with SR 
141716A, suggesting that they are mediated by the CB1R. Interestingly, application of 
SR141716A alone had no effect on the levels of phosphorylated ERK1/2 or Akt. 
Previous studies have shown that SR141716A can exhibit either an inverse agonism 
or an apparent neutral competitive antagonism, depending on the assay system. For 
instance, cannabinoid agonists mediated the inhibition of depolarization-induced 
epinephrine release from hippocampal slices, an effect that was antagonized by 
SR141716A (Schlicker et al., 1997), but when administered alone, SR141716A had 
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no effect on the stimulated release of norepinephrine from human hippocampal slices 
(Selley et al., 1996). Our observations suggest that in hiPSC-neuronal cultures, 
SR141617A may have no activity in the absence of an agonist or inverse agonist, but 
can block the activity of either. Overall, previous data and ours suggest that both 
endogenous and exogenous cannabinoids affect the ERK1/2 and Akt signaling 
pathways. It is possible that in different model systems, CB1R activation triggers 
different signaling pathways to regulate downstream gene expression and neuronal 
processes. The specific pharmacology of CB1R signaling is not well understood, and 
further research is necessary to describe how endogenous, exogenous and synthetic 
cannabinoids act on CB1R and how they may or may not interact to trigger or inhibit 
downstream signaling pathways. One possibility is that owing to the repertoire of 
signaling proteins that are expressed in these developing neurons, that 2AG and Δ9-
THC couple the CB1R to the negative regulation of these kinases via a mechanism 
known as biased receptor signaling (Kenakin, 2019).  
Overall, the results of the present study suggest that exogenous 2AG and Δ9-
THC are able to induce morphological changes in young hiPSC-derived glutamatergic 
neurons, further supporting the notion that this cellular system is a good model for 
investigating cannabinoid function in early development (Guennewig et al., 2018). A 
recent study showed that pluripotent stem cells derived from males and females 
display more than 200 differentially expressed autosomal genes (Ronen and 
Benvenisty, 2014). In addition, sex differences in neuronal morphology have been 
reported in hiPSC-neurons in a model of traumatic axonal injury (Dolle et al., 2018). 
This proof-of-concept study has demonstrated that male hiPSC-neurons are 
responsive to pharmacological manipulation of the cannabinoid system. Future 
studies using hiPSC-neurons derived from neurotypical females would allow an 
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examination of potential sex differences in neuronal development and responses to 
cannabinoids.  
 CB1Rs were first identified as the main neuronal receptor for Δ9-THC and are 
one of the most abundant G protein-coupled receptors in the brain(Matsuda et al., 
1990). CB1Rs and endocannabinoids are also highly expressed in the fetal brain and 
implicated in neuronal development processes such as neurite growth and axonal 
pathfinding (Njoo et al., 2015; Tortoriello et al., 2014; Vitalis et al., 2008; Watson et al., 
2008; Wu et al., 2010; Zorina et al., 2010). In this present study, we have examined 
the endocannabinoid 2-AG and its effects in hiPSC-neurons. Anandamide is another 
endocannabinoid that is also present during development. Future studies using a 
wider range of CB receptor-specific agonists would provide a deeper understanding 
of the pharmacology underlying eCB signaling in hiPSC-neurons. We show that 
exogenous cannabinoids modulate neurite outgrowth in hiPSC-neurons, and previous 
studies have shown that endogenous and exogenous cannabinoids alter synaptic 
activity and synaptic protein expression in developing human hiPSC-derived neurons 
(Obiorah et al., 2017; Stanslowsky et al., 2017). Moreover, as Δ9-THC has recently 
been shown to alter expression of genes associated with neurodevelopmental and 
psychiatric disorders, there is evidence for perturbations of shared molecular 
pathways potentially exacerbated by Δ9-THC (Guennewig et al., 2018). Whether or 
not overstimulation by exogenous cannabinoids or abnormal levels of 
endocannabinoids during neurodevelopment may perturb normal physiological 
processes, potentially contributing to neurodevelopmental and psychiatric disorders 
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Figure 1: Generation of cortical neurons from hiPSCs. (A) Schematic of hiPSC 
differentiation protocol used. (B) Representative images of hiPSCs, NPCs and 
neurons immunostained for markers of specific cell linages. (C) Number of DAPI 
positive cells expressing markers of hiPSC, NPC and neuronal cell fate; error bars 
represent standard deviations (SD). (D-G) Expression profile of cell fate markers 
determined between day 7 and 50 following induction of neural differentiation; error 
bars represent SD.   
 
Figure 2: Expression of cannabinoid receptors in hiPSC-neurons. (A) Expression 
of CB1R in NPCs and neurons in three independent hiPSC lines. In all three lines, 
CB1R expression increases as cells differentiate into neurons: (F(2,12)=6.49, p < 0.05, 
Bonferroni Post Hoc, ***, p < 0.001, two-way ANOVA; n = 3 independent cultures for 
each line). (B) Comparison of the expression of CB1R, CB2R, GPR55 and TRPV1 
receptors in day 30 hiPSC-neurons. Whereas CB1R is highly expressed, no 
expression of CB2R, GPR55 or TRPV1 receptors was detected in three hiPSC-lines: 
(F(6,12)=1.896, p < 0.05, Bonferroni Post Hoc, ***, p < 0.001, two-way ANOVA; n = 2 
independent cultures for each line). (C) Western blot demonstrating expression of 
CB1R in day 30 hiPSC-neurons derived from 2 independent hiPSC-lines. A prominent 
band is observed at ~53 kDa, predicted molecular weight of CB1R. (D) Representative 
confocal images of day 30 hiPSC-neurons immunostained for MAP2 (dendrites) and 
CB1R. Immunoreactive puncta for CB1R can be found along MAP2-positive neurites. 
Insets are of high magnification zooms of dendrite highlighted by white box in main 




Figure 3: Negative regulation of neurite outgrowth in hiPSC-neurons by 2AG. (A) 
Representative images of MAP2 stained day 30 hiPSC-neurons as imaged using the 
Opera Phenix High Content Imager. (B) Assessing of the number of DAPI-positive 
MAP2 neurons demonstrates no difference on overall neuronal number across 
conditions. Data are presented for each individual hiPSC-line: data was generated 
from 3 independent cultures for each independent hiPSC line. (C, D) Assessment of 
average neurite number (C) and average branch number (D) revealed no difference 
between conditions. (E) Treatment with 2AG for 24 hours significantly reduced total 
neurite length compared to vehicle control. Scale bar = 50 µm. 
 
Figure 4: Δ9-THC negatively influences neurite outgrowth in hiPSC-neurons. (A) 
Representative images of MAP2 stained day 30 hiPSC-neurons following 24 hour 
treatment with vehicle or Δ9-THC, as imaged using the Opera Phenix High Content 
Imager. (B) Assessing of the number of DAPI-positive MAP2 neurons demonstrates 
no difference on overall neuronal number across conditions. Data are presented for 
each individual hiPSC-line: data was generated from 3 independent cultures for each 
independent hiPSC line. (C, D) Assessment of average neurite number (C) and 
average branch number (D) revealed no difference between conditions. (E) Treatment 
with Δ9-THC for 24 hours significantly reduced total neurite length compared to vehicle 
control. Scale bar = 50 µm. 
 
Figure 5: 2AG decreases ERK1/2 phosphorylation and Δ9-THC negative regulate 
ERK1/2 and Akt phosphorylation. (A) Western blot analysis of day 30 hiPSC-
neurons treated with 2AG for 15 or 30 minutes compared to vehicle control conditions. 
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Western blots probed for total and pERK1/2, revealed a significant decrease in active 
(phosphorylated) ERK1/2 levels after 30 minutes of 2AG treatment (F(2,6)=6.593, p < 
0.05, Tukey Post Hoc, *, p < 0.05, one-way ANOVA; n = 3 per condition from 3 
independent hiPSC-lines). (B, C) Western blot analysis of day 30 hiPSC-neurons 
treated with 2AG for 15 or 30 minutes compared to vehicle control conditions. Western 
blots probed for total and active (phosphorylated) Akt and GSK3β; no difference was 
observed between conditions. (D) Western blot analysis of day 30 hiPSC-neurons 
treated with Δ9-THC for 15 or 30 minutes compared to vehicle control conditions. 
Western blots probed for total and pERK1/2, revealed a significant decrease in active 
(phosphorylated) ERK1/2 levels after 30 minutes of Δ9-THC treatment (F(2,6)=8.299, 
p < 0.05, Tukey Post Hoc, *, p < 0.05, one-way ANOVA; n = 3 per condition from 3 
independent hiPSC-lines). (E) Assessment of pAkt levels also revealed a reduction in 
active levels of Akt following treatment with Δ9-THC (F(2,6)=9.557, p < 0.05, Tukey 
Post Hoc, *, p < 0.05, one-way ANOVA; n = 3 per condition from 3 independent hiPSC-
lines). (F) Cell lysates were also assessed for levels of active (phosphorylated) 
GSK3β; no difference was observed between conditions. Full blots are shown in 
Supplementary Figure 5 & 6. 
 
Figure 6: CB1R antagonist SR 141716A blocks negative regulation of ERK1/2 
and Akt phosphorylation by 2AG and Δ9-THC. (A) Western blot analysis of day 30 
hiPSC-neurons treated with vehicle, 2AG or Δ9-THC (30 minutes) with or without pre-
treatment with inverse antagonist SR 141716A (20 nM). Western blots probed for total 
and pERK1/2, revealed that SR 141716A blocked 2AG or Δ9-THC induced decrease 
in active (phosphorylated) ERK1/2 levels after 30 minutes. (B) Cell lysates were also 
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assessed for levels of pAkt. This revealed that SR 141716A blocked Δ9-THC decrease 
in pAkt levels. Full blots are shown in Supplementary Figure 7. 
 
Figure 7: Negative regulation of neurite outgrowth by 2AG and Δ9-THC is 
attenuated by SR 141716A. (A) Representative images of MAP2 stained day 30 
hiPSC-neurons following 24 hour treatment with vehicle, 2AG or Δ9-THC, with or 
without co-treatment with inverse antagonist SR 141716A (20 nM). (B) Assessing of 
total neurite length in all conditions. Data are presented for each individual hiPSC-line: 
data was generated from 3 independent cultures for each independent hiPSC line. 
Treatment with 2AG or Δ9-THC for 24 hours significantly reduced total neurite length 









Antibody Type   Host Dilution Supplier Catalog 
Number 
NESTIN Monoclonal Mouse 1:500 R&D 
Systems 
MAB1259 
OCT4 Monoclonal Mouse 1:200 Santa cruz Sc5279 
PAX6 Polyclonal Rabbit 1:200 Proteintech 
grPooup 
12323-1-AP 
SOX11 Polyclonal Rabbit 1:50 Santa cruz Sc20096 
NANOG Polyclonal Goat  5ug/ml R&D 
Systems 
AF1997 
ZNF521 Polyclonal Rabbit 1:100 Atlas 
Antibodies 
HPA023056 
FOXG1 Polyclonal Rabbit 1:500 Abcam Ab18259 
TBR1 Polyclonal Rabbit 1:500 Abcam Ab31940 
TBR2 Polyclonal Rabbit 1ug/ml Abcam Ab23345 
BRN2 Polyclonal Rabbit 1:500 Santa cruz Sc28594 
MAP2 Polyclonal Chicken 1:1000 Abcam Ab92434 
CB1R Polyclonal Rabbit 1:50 Abcam ab23703 
Erk 1/2 Monoclonal Mouse 1:2000 Cell 
signaling 
L34F12 










Polyclonal Rabbit 1:1000 Cell 
signaling 
D85E12 
Akt Monoclonal Mouse 1:2000 Cell 
signaling 
40D4 
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Supplementary Figures 1-8 
Human induced pluripotent stem cells (hiPSCs) 
 hiPSC lines were generated from primary keratinocytes. Briefly, 1 x 105 primary 
hair root keratinocytes were reprogramed by introducing OCT4, SOX2, KLF4 and C-
MYC factors with a CytoTune-iPS 2.0 Sendai expressing Reprogramming Kit 
(ThermoFisher, A16517). Transformed keratinocytes were plated onto an irradiated 
MEF feeder layer (Millipore) supplemented Epilife medium for ten days before 
switching to 'hES media', which consisted of KO-DMEM/F12 supplemented with 20% 
Knock-out serum replacement, Non-essential amino acids, Glutamax, -
mercaptoethanol (all from Life Technologies) and bFGF (10 ng/ml; Peprotech). After 
a further two weeks, reprogrammed colonies were selected and plated on Geltrex (Life 
technologies) coated Nunc treated multidishes (Thermo Scientific) into E8 media (Life 
Technologies). hiPSCs reprograming was validated by genome-wide expression 
profiling using Illumina Beadchip v4 and the bioinformatics tool 'Pluritest'. Additionally, 
the  tri-lineage differentiation potential was stablished by embryoid body formation; 
ICCs to validate the expression of different pluripotency markers including Nanog, 
OCT4, SSEA4 and TRA1-81 and the alkaline phosphatase activity by Alkaline 
phosphatase expression kit (Milipore).  The genomic stability was determined by G-
banded karyotyping. hiPSCs were incubated in hypoxic conditions at 37°C and 
maintained in E8 media replaced every 24 hours until the cells monolayer reach ~95% 
confluence.   
 
Electrophysiology 
Electrophysiological recordings were obtained from hiPSC derived neurons 
differentiated for 64 days in vitro. Patch pipettes (4.0–7.5 MΩ) were pulled from 
borosilicate glass capillary tubes using a P97 Flaming/Brown Micropipette Puller 
(Sutter Instruments). The internal patch solution contained (in mM) 135 K-Gluconate, 
10 KCl, 1 MgCl2, 10 HEPES, 2 Na2 -ATP and 0.4 Na3 -GTP. All recordings were 
conducted at room temperature in neurobasal medium (0.1% BDNF, 0.01% Ascorbic 
acid, 2% B27, 1% Glutamax). Spontaneous currents were measured by whole cell 
voltage clamp recordings at a holding potential of −70mV.  Current-voltage recordings 
were conducted from a holding potential of -70mV with increasing voltage steps of 
2mV increments up to +20mV. Action potentials were recorded in current clamp from 
a holding potential of -6 mV, with 2pA current injection increments each of 500ms. 
Data were generated and acquired using an EPC10 amplifier (Heka Instruments, 




Supplementary Figure 1. Validation of hiPSC lines. (A) HiPSCs were 
immunostained for pluripotency markers Oct4, Nanog and Tra-18-1. (B) HiPSCs were 
further tested for their ability to generate cells from the 3 germ layers using an 
embyobody methodology (Cocks et al., 2014). All three hiPSC line demonstrated the 


















Supplementary Figure 2. Characterization of hiPSC-neurons. (A) Representative 
images of day 30 hiPSC-neurons immunostained for glia markers GFAP and S100β. 
(B & C) Representative images of day 50 hiPSC-neuron immunostained for 
glutamatergic markers. (D) Number of MAP2 positive cells expressing VGlut1, PSD95, 
GluN1 and synapsin 1; error bars represent standard deviations (SD). (E-F) Whole 
cell patch clamp recordings obtained from day 64 hiPSC derived neurons. (E) Action 
potentials recorded in response to increasing current injection (24pA, 28pA and 32pA) 
in current clamp. (F) Voltage clamp recordings of the voltage activated currents elicited 
in response to 10ms long voltage steps from a holding potential of -70mV. 
Representative I-V traces at 10mV voltage increments. (G) Representative 






Supplementary Figure 3. Characterization of endocannaboid system in hiPSC-
neurons. (A) Expression of DAGLA, FAAH and MGLL CB1R in NPCs and neurons in 
three independent hiPSC lines. DAGLA expression increased as cells differentiate into 
neurons, whereas FAAH and MGLL expression did not altered between these two time 
points (two-way ANOVA; n = 3 independent cultures for each line).(B) Pre-absorption 
of CB1R antibody with antigenic peptide abolishes bands around 53kDa, predicted 




Supplementary Figure 4. Effect of low concentrations of 2AG and Δ9-THC on 
neurite outgrowth in hiPSC-neurons. (A) Assessing total neurite length revealed 
that 50 nM 2AG (24 hours) had no effect on neurite outgrowth compared to vehicle 
control. (B) Assessment of total neurite length demonstrated that treatment with 50 


































































Supplementary Figure 5. Full length blot of western blot shown in main Figure 5 A to 
C. 
Supplementary Figure 6. Full length blot of western blot shown in main Figure 5 D to 
F.  




Supplementary Figure 8. (A) Representative images of MAP2 stained day 30 hiPSC-
neurons following 24 hour treatment with vehicle or U0126 (10 μM). (B) Assessing of 
total neurite length in all conditions. Data are presented for each individual hiPSC-line: 
data was generated from 3 independent cultures for each independent hiPSC line. 
Treatment with U026 significantly reduced total neurite length compared to vehicle 
control. Scale bar = 50 µm. 
 
